Dr. Thomas VanCott, Ph.D serves as the Chief Executive Officer and President at ABL, Inc. and served as its Executive Vice President of Operations. Dr. VanCott joined ABL in February 2004. From 1990 to 2003, he led the preclinical HIV vaccine development efforts for the U.S. Military HIV Research Program. He serves as the Co-Principal Investigator of a multi-year master contract at the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, to perform preclinical development of promising HIV-1 vaccines and microbicides. Dr. VanCott received his Bachelors degree in Chemistry from Dickinson College and his Doctrate degree in Physical Chemistry from the University of Virginia. 

ABL provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. ABL’s contract research teams have decades of experience with immunoassays, developing custom assays and panels to support human clinical trials and preclinical animal studies. We routinely work with clients to design and run immunogenicity studies, biomarker analyses and other evaluations to better understand the impact of cutting-edge therapies: the mechanism of action, correlates of protection, pharmacokinetic/pharmacodynamics studies and other critical safety and efficacy data